ArticlePDF Available

Randomized Controlled Trial of Yogic Meditation Techniques for Patients With Obsessive-Compulsive Disorder

Authors:

Abstract

The objective of this study was to compare efficacy of two meditation protocols for treating patients with obsessive-compulsive disorder (OCD). Patients were randomized to two groups-matched for sex, age, and medication status-and blinded to the comparison protocol. They were told the trial would last for 12 months, unless one protocol proved to be more efficacious. If so, groups would merge, and the group that received the less efficacious treatment would also be afforded 12 months of the more effective one. The study was conducted at Children's Hospital, San Diego, Calif. Patients were selected according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised (DSM-III-R) criteria and recruited by advertisements and referral. At baseline, Group 1 included 11 adults and 1 adolescent, and Group 2 included 10 adults. Group 1 employed a kundalini yoga meditation protocol and Group 2 employed the Relaxation Response plus Mindfulness Meditation technique. Baseline and 3-month interval testing was conducted using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Symptoms Checklist-90-Revised Obsessive Compulsive (SCL-90-R OC) and Global Severity Index (SCL-90-R GSI) scales, Profile of Moods scale (POMS), Perceived Stress Scale (PSS), and Purpose in Life (PIL) test. Seven adults in each group completed 3 months of therapy. At 3 months, Group 1 demonstrated greater improvements (Student's independent groups t-test) on the Y-BOCS, SCL-90-R OC and GSI scales, and POMS, and greater but nonsignificant improvements on the PSS and PIL test. An intent-to-treat analysis (Y-BOCS) for the baseline and 3-month tests showed that only Group 1 improved. Within-group statistics (Student's paired t-tests) showed that Group 1 significantly improved on all six scales, but Group 2 had no improvements. Groups were merged for an additional year using Group 1 techniques. At 15 months, the final group (N=11) improved 71%, 62%, 66%, 74%, 39%, and 23%, respectively, on the Y-BOCS, SCL-90-R OC, SCL-90-R GSI, POMS, PSS, and PIL; P<0.003 (analysis of variance). This study demonstrates that kundalini yoga techniques are effective in the treatment of OCD.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

!"342!#4
4HEOBJECTIVEOFTHISSTUDYWASTOCOMPAREEFFICACYOFTWO
MEDITATIONPROTOCOLSFORTREATINGPATIENTSWITHOBSESSIVECOM
PULSIVEDISORDER/#$0ATIENTSWERERANDOMIZEDTOTWO
GROUPSMATCHEDFORSEXAGEANDMEDICATIONSTATUSAND
BLINDEDTOTHECOMPARISONPROTOCOL4HEYWERETOLDTHETRIAL
WOULDLASTFORMONTHSUNLESSONEPROTOCOLPROVEDTOBE
MOREEFFICACIOUS)FSOGROUPSWOULDMERGEANDTHEGROUP
THATRECEIVEDTHELESSEFFICACIOUSTREATMENTWOULDALSOBE
AFFORDEDMONTHSOFTHEMOREEFFECTIVEONE4HESTUDYWAS
CONDUCTEDAT#HILDRENS(OSPITAL3AN$IEGO#ALIF0ATIENTS
WERESELECTEDACCORDINGTO$IAGNOSTICAND3TATISTICAL-ANUAL
OF-ENTAL$ISORDERS4HIRD%DITION2EVISED$3-)))2
CRITERIAANDRECRUITEDBYADVERTISEMENTSANDREFERRAL!TBASE
LINE'ROUPINCLUDEDADULTSANDADOLESCENTAND'ROUP
INCLUDEDADULTS'ROUPEMPLOYEDAKUNDALINIYOGA
MEDITATIONPROTOCOLAND'ROUPEMPLOYEDTHE2ELAXATION
2ESPONSEPLUS-INDFULNESS-EDITATIONTECHNIQUE"ASELINE
ANDMONTHINTERVALTESTINGWASCONDUCTEDUSINGTHE9ALE
"ROWN/BSESSIVE#OMPULSIVE3CALE9"/#33YMPTOMS
#HECKLIST2EVISED/BSESSIVE#OMPULSIVE3#,2/#
AND'LOBAL3EVERITY)NDEX3#,2'3)SCALES0ROFILE
OF-OODSSCALE0/-30ERCEIVED3TRESS3CALE033AND
0URPOSEIN,IFE0),TEST3EVENADULTSINEACHGROUPCOM
PLETEDMONTHSOFTHERAPY!TMONTHS'ROUPDEMON
STRATEDGREATERIMPROVEMENTS3TUDENTSINDEPENDENTGROUPS
TTESTONTHE9"/#33#,2/#AND'3)SCALESAND
0/-3ANDGREATERBUTNONSIGNIFICANTIMPROVEMENTSONTHE
033AND0),TEST!NINTENTTOTREATANALYSIS9"/#3FOR
THEBASELINEANDMONTHTESTSSHOWEDTHATONLY'ROUP
IMPROVED7ITHINGROUPSTATISTICS3TUDENTSPAIREDTTESTS
SHOWEDTHAT'ROUPSIGNIFICANTLYIMPROVEDONALLSIXSCALES
BUT'ROUPHADNOIMPROVEMENTS'ROUPSWEREMERGEDFOR
ANADDITIONALYEARUSING'ROUPTECHNIQUES!TMONTHS
THEFINALGROUP.IMPROVED
ANDRESPECTIVELYONTHE9"/#33#,2/#
3#,2'3)0/-3033AND0),0ANALYSISOF
VARIANCE4HISSTUDYDEMONSTRATESTHATKUNDALINIYOGATECH
NIQUESAREEFFECTIVEINTHETREATMENTOF/#$
#.33PECTRUMS
).42/$5#4)/.
/BSESSIVECOMPULSIVEDISORDER/#$ISONEOFTHE
MOSTDISABLINGOFTHEANXIETYDISORDERS
!CONDITION
WITHALIFELONGCOURSE/#$ISESTIMATEDTOBETHE
FOURTHMOSTCOMMONPSYCHIATRICDISORDERFOLLOWINGPHO
BIASSUBSTANCEABUSEDISORDERSANDTHEMAJORDEPRES
SIVEDISORDERSANDISTWICEASCOMMONASSCHIZOPHRENIA
ANDPANICDISORDER
/#$OFTENBEGINSDURINGCHILDHOOD
ORADOLESCENCEHASALIFETIMEPREVALENCERATEOF
TO
ANDHASPROVENTOBEREFRACTORYTOTRADITIONAL
INSIGHTORIENTEDPSYCHOTHERAPY
$AVID3HANNAHOFF+HALSAISRESEARCHGROUPDIRECTOROF4HE2ESEARCH'ROUPFOR-IND"ODY$YNAMICSATTHE)NSTITUTEFOR.ONLINEAR3CIENCE5NIVERSITYOF
#ALIFORNIA3AN$IEGOANDPRESIDENTOF4HE+HALSA&OUNDATIONFOR-EDICAL3CIENCE$EL-AR#!-S2AYISACONSULTINGPSYCHOTHERAPISTINPRIVATEPRACTICE
IN3AN$IEGO#!$R,EVINEISAPROFESSORINTHE$EPARTMENTOF0SYCHIATRYATTHE5NIVERSITYOF#ALIFORNIA3AN$IEGOANDCHAIRMANOFTHE$EPARTMENTOF
0SYCHIATRY#HILDRENS(OSPITALIN3AN$IEGO$R'ALLENWASANASSISTANTMEMBEROFTHE$EPARTMENTOF.EUROPHARMACOLOGYAT4HE3CRIPPS2ESEARCH)NSTITUTE
,A*OLLA#!ANDISNOWVICEPRESIDENTOFCLINICALRESEARCH#.3ANDCLINICALOPERATIONSAT0HARMACIA5P*OHN+ALAMAZOO-)$R3CHWARTZISASSISTANT
PROFESSORINTHE$EPARTMENTOF.EUROPHARMACOLOGYAT4HE3CRIPPS2ESEARCH)NSTITUTEANDAVISITINGSCHOLARAT4HE2ESEARCH'ROUPFOR-IND"ODY$YNAMICS
)NSTITUTEFOR.ONLINEAR3CIENCE$R3IDOROWICHISAVISITINGSCHOLARAT4HE2ESEARCH'ROUPFOR-IND"ODY$YNAMICS)NSTITUTEFOR.ONLINEAR3CIENCE
!CKNOWLEDGMENTS
#ONTRIBUTORS$AVID3HANNAHOFF+HALSAISTHEGUARANTORANDHADTHEORIGINALIDEAFORTHESTUDYOBTAINEDGRANTFUNDINGWITH$R,EVINEANDACTEDAS
THEPRINCIPALINVESTIGATOR4HEEXPERIMENTWASDESIGNEDBY$AVID3HANNAHOFF+HALSA$R,EVINE-S2AY$R'ALLEN$R3CHWARTZAND$R3IDOROWICH
$AVID3HANNAHOFF+HALSADESIGNEDTHEGROUPPROTOCOLAND$AVID3HANNAHOFF+HALSAAND-S2AYDESIGNEDTHEGROUPPROTOCOL$ATAANALYSESWERE
CARRIEDOUTBY$AVID3HANNAHOFF+HALSAAND-S2AYWITHADVICEFROM$RS'ALLEN,EVINE3CHWARTZAND3IDOROWICH!LLAUTHORSCONTRIBUTEDTOTHE
DISCUSSIONOFCOREIDEAS$AVID3HANNAHOFF+HALSAHADRESPONSIBILITYFORWRITINGTHEPAPERWITHCONTRIBUTIONSFROMALLOTHERAUTHORS
4HEAUTHORSTHANK0AUL3HRAGG"3-3AND2EENA$EUTSCH0H$5NIVERSITYOF#ALIFORNIA3AN$IEGO'ENERAL#LINICAL2ESEARCH#ENTERFORBIOSTATISTICALASSISTANCE
&UNDING"IOSTASTICALASSISTANCEWASSUPPORTEDINPARTBYRESEARCHGRANT-22FROMTHE'ENERAL#LINICAL2ESEARCH#ENTER0ROGRAM.ATIONAL
)NSTITUTESOF(EALTH"ETHESDA-$)NADDITIONTHISWORKWASSUPPORTEDINPARTBYRESEARCHGRANT222FROMTHE/FFICEOF!LTERNATIVE-EDICINE
.ATIONAL)NSTITUTESOF(EALTH"ETHESDA-$TO$AVID3HANNAHOFF+HALSAANDBYTHE7ALETZKY#HARITABLE,EAD4RUSTAND-R*OHN$E"EER
#ORRESPONDENCE$AVID33HANNAHOFF+HALSA4HE2ESEARCH'ROUPFOR-IND"ODY$YNAMICS)NSTITUTEFOR.ONLINEAR3CIENCE5NIVERSITYOF#ALIFORNIA3AN$IEGO
'ILMAN$R,A*OLLA#!nDSK ROUTHUCSDEDU
#ONFLICTOFINTERESTNONE
&EATURE!RTICLE/RIGINAL2ESEARCH
2ANDOMIZED#ONTROLLED4RIALOF9OGIC
-EDITATION4ECHNIQUESFOR0ATIENTS7ITH
/BSESSIVE#OMPULSIVE$ISORDER
"Y$AVID33HANNAHOFF+HALSA,ESLIE%2AY-3-&##3AUL,EVINE-$
#HRISTOPHER#'ALLEN-$0H$"ARRY*3CHWARTZ0H$AND*OHN*3IDOROWICH0H$
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

0HARMACOLOGICMANAGEMENTANDBEHAV
IORTHERAPY"4CONSISTINGOFEXPOSUREAND
RESPONSEPREVENTIONAREUSEDINTREATMENT
(OWEVERITHASBEENREPORTEDTHATTO
OFPATIENTSSHOWONLYMINIMALIMPROVE
MENTORNOCHANGEWITHTHEUSEOFSEROTONIN
REUPTAKEINHIBITORSALONE
ANDTHATUPTOONE
THIRDOFPATIENTSREMAINUNIMPROVEDAFTER
APPARENTLYADEQUATEDRUGTREATMENT
4HESE
PATIENTSHAVEBEENCALLEDDRUGTREATMENT
RESISTANT
)NRESPONDERSMEDICATIONPRO
DUCESASYMPTOMREDUCTIONOFTOAT
BESTANDPATIENTSTENDTOREMAINCHRONICALLY
SYMPTOMATICTOSOMEDEGREEDESPITEUSEOF
THEMOSTEFFECTIVEPHARMACOLOGICINTERVEN
TIONS
!LTHOUGHADECREASEOFTOIN
THEMEAN9ALE"ROWN/BSESSIVE#OMPULSIVE
3CALE9"/#3
SCORESMAYREPRESENTACLINI
CALLYMEANINGFULCHANGEINSYMPTOMSEVERITY
THEREISCLEARLYROOMFORIMPROVEMENT
$ISCONTINUATIONOFPHARMACOLOGICTREAT
MENTISALMOSTALWAYSASSOCIATEDWITHCOM
PLETE RELAPSE
)N ADDITION+OBAKET
AL
RECENTLYCONDUCTEDAMETAANALYSISTO
COMPARE"4WITHPHARMACOLOGICTHERAPY
THATCONSISTEDOFSEROTONINREUPTAKEINHIBI
TORSCONCLUDINGTHATTHETWOTREATMENTSWERE
COMPARABLE4HESIZEABLEPERCENTAGEOFTREAT
MENTREFRACTORYPATIENTSTHELIMITEDSHORT
ANDLONGTERMSUCCESSANDADVERSEEFFECTSOF
MEDICATIONANDTHEFACTTHATIMPROVEMENTIN
RITUALIZINGWITH"4OFTENFAILSTOBRINGABOUTA
SIGNIFICANTREDUCTIONINGENERALIZEDANXIETY

ORDEPRESSION

ALLSUGGESTANEEDTOINVESTI
GATEALTERNATIVETREATMENTMODALITIES
2ECENTLYASMALLUNCONTROLLEDTRIALDEM
ONSTRATEDTHATKUNDALINIYOGA+9TECHNIQUES
ARESUCCESSFULINIMPROVING/#$SYMP
TOMS

&IVEOFEIGHTPATIENTSCOMPLETEDTHIS
MONTHINVESTIGATIONSHOWINGAMEAN
9"/#3IMPROVEMENTOF4HECOM
PLETERS ALSO ACHIEVED IMPROVEMENTS OF
ANDRESPECTIVELYONTHE
3YMPTOM#HECKLIST2EVISED/BSESSIVE
#OMPULSIVE3#,2/#
AND'LOBAL
3EVERITY)NDEX'3)SUBSCALES)NTHESEFIVE
PARTICIPANTS/#$WASPREVIOUSLYSTABILIZED
WITHFLUOXETINEFORMORETHANMONTHSPRIOR
TOTHESTARTOFTHESTUDY/FTHEFIVETHREE
WERECOMPLETELYFREEOFMEDICATIONFORATLEAST
MONTHSPRIORTOSTUDYENDANDTHENEEDFOR
MEDICATIONINTHEREMAININGTWOWASSIGNIF
ICANTLYREDUCED/NEYEARLATERFOUROFTHE
FIVEPATIENTSHADREMAINEDOFFMEDICATIONFOR
PERIODSRANGINGBETWEENANDMONTHS
WITHLASTINGIMPROVEMENT
4HEABOVEFINDINGSOFSUSTAINEDANDCLINI
CALLYSIGNIFICANTIMPROVEMENTWEREOBTAINED
INANUNCONTROLLEDTRIAL(EREWEREPORT
RESULTSAFTERCOMPARINGTHEPROTOCOLFROMTHE
UNCONTROLLEDTRIAL

WHICHINCLUDEDAYOGIC
BREATHINGTECHNIQUECLAIMEDTOBESPE
CIFICFORTREATING/#$WITHAVERYDIFFERENT
MEDITATIONPROTOCOL4HEHYPOTHESISTESTED
HEREISTHATTHISDISORDERSPECIFICTECHNIQUE
WOULDBEREQUIREDFOREFFICACYANDTHATMED
ITATIONTECHNIQUESINGENERALMAYNOTBE
EFFECTIVE0RELIMINARYRESULTSATMONTH
OFTHISMONTHTRIALFROMONEOFTHESIX
SCALESREPORTEDHERE9"/#3WEREPUB
LISHEDEARLIER

-%4(/$3
0ROTOCOL
0ATIENTSWITH/#$WERERECRUITEDTHROUGH
ATELEVISIONNEWSCOMMENTARYNEWSPAPER
ADVERTISEMENTANDPHYSICIANREFERRAL!LL
BUTONEPATIENTHADAPREVIOUSPRINCIPAL
DIAGNOSISOF/#$
)NCLUSION#RITERIA
!LLDIAGNOSESWERECONFIRMEDINASEMI
STRUCTUREDINTERVIEWFORSUITABILITYUSING
$IAGNOSTICAND3TATISTICAL-ANUALOF-ENTAL
$ISORDERS4HIRD%DITION2EVISED
$3-
)))2CRITERIA FOR/#$WHICH
REQUIRESSYMPTOMSTOBEPRESENTFORAMINI
MUMOFMONTHSBEFOREDECLARINGADIAGNO
SISOF/#$!MINIMUMSCOREOFONTHE
9"/#3FORTHEITEMTOTALWASREQUIRED
FORADULTS)FTHEPATIENTSWERETAKINGMEDICA
TIONTHEYHADTOBEDOSESTABILIZEDFORATLEAST
MONTHSPRIORTOENTRY4HEMINIMUMAGEFOR
INCLUSIONWASYEARS
%XCLUSION#RITERIA
0ATIENTSWEREEXCLUDEDIFTHEYSMOKEDHAD
ASUBSTANCEABUSEDISORDERORHADSPINALOR
OTHERPHYSICALLYLIMITINGPROBLEMSTHATCOULD
INTERFEREWITHTHEMEDITATIONPRACTICE4HESE
PROBLEMSINCLUDEDBEINGEXCESSIVELYOVER
WEIGHTSEIZUREDISORDERSPULMONARYDISORDERS
EGSEVEREASTHMAOREMPHYSEMAHYPER
TENSIONSINCETHE+9PROTOCOLINCLUDESTWO
TECHNIQUESFORHOLDINGTHEBREATHANDTENSING
MUSCLESANDOTHERCARDIOVASCULARPROBLEMS
!LSOEXCLUDEDWEREPATIENTSWITHTHEFOL
LOWING$3-)))2PSYCHIATRICCONDITIONSAS
THEIRPRIMARYDISORDERSCHIZOPHRENIAMAJOR
DEPRESSIVEDISORDERBIPOLARDISORDERMENTAL
RETARDATIONANOREXIANERVOSAANDBULIMIA
NERVOSA0ATIENTSWITH4OURETTESYNDROME
&EATURE!RTICLE/RIGINAL2ESEARCH
h4HEHYPOTHESIS
TESTEDHEREISTHAT
THISDISORDERSPECIFIC
TECHNIQUEWOULD
BEREQUIREDFOREFFICACY
ANDTHATMEDITATION
TECHNIQUESINGENERAL
MAYNOTBEEFFECTIVEv
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

TRICHOTILLOMANIAORNAILBITINGASTHEIRONLY
COMPULSIONWEREALSOEXCLUDEDASWERE
PATIENTSWITHOUTREGULARTRANSPORTATIONTOTHE
STUDYSITE
)NFORMED#ONSENT
0RIORTOENROLLMENTALLPATIENTSWERE
INFORMEDTHATTHISWOULDBEACONTROLLEDSTUDY
COMPARINGTWOMEDITATIONPROTOCOLSWITHTEST
INGATMONTHINTERVALSTODETERMINEIFONE
PROTOCOLWASSUPERIOR)FONEPROTOCOLPROVED
TOBESUPERIORTHEGROUPSWOULDBECOMBINED
4HOSEWHOHADUSEDTHELESSEFFICACIOUSPRO
TOCOLINITIALLYWOULDALSORECEIVEMONTHS
OFTHEMOREEFFICACIOUSPROTOCOLALLOWING
FORTWOPOSSIBLESTUDYPHASES0ATIENTSWERE
INFORMEDTHATTHEYCOULDNOTBEGINNEWMEDI
CATIONSFORANYPSYCHIATRICDISORDERSDURING
THESTUDYIFTHEYWISHEDTOREMAINENROLLED
4HEYWEREALSOTOLDTHATTHEYWERENOTALLOWED
TOPARTICIPATEINOTHERFORMSOFTHERAPYFOR
/#$WHILEPARTICIPATINGINTHESTUDY4HEY
WOULDHOWEVERBEALLOWEDTOREDUCEORELIMI
NATETHEIRESTABLISHEDMEDICATIONS
!FTERDESCRIBINGTHESTUDYANDTHEPOSSIBLE
ADVERSEEFFECTSIETEMPORARYMUSCLESORENESS
WEOBTAINEDWRITTENINFORMEDCONSENTFROMALL
PARTICIPANTS4HESTUDYWASCONDUCTEDINCOM
PLIANCEWITHTHE#ODEOF%THICSOFTHE7ORLD
-EDICAL!SSOCIATION$ECLARATIONOF(ELSINKI
)NTERVENTIONS
7EEKLYMEETINGSWEREHELDON7EDNESDAY
EVENINGSFROMTO0-'ROUPWAS
INSTRUCTEDBY$33+ANEXPERTWITHYEARS
OFPERSONALANDTEACHINGEXPERIENCEIN+9
THERAPYBUTNOFORMALTRAININGASAPSYCHO
THERAPIST'ROUPEMPLOYEDTHE+9PROTOCOL
WHICHREQUIREDAPPROXIMATELYHOURTOCOM
PLETE!LLPATIENTSWEREINSTRUCTEDTOPRACTICE
THEIRRESPECTIVEPROTOCOLSONADAILYBASISTOTHE
BESTOFTHEIRABILITIESONALLSUBSEQUENTDAYS
!COMPLETEDESCRIPTIONOFTHE+9PROTO
COLWASPUBLISHEDPREVIOUSLYBY3HANNAHOFF
+HALSA

)TINCLUDESEIGHTPRIMARYTECHNIQUES
INCLUDING AYOGIC BREATHINGTECHNIQUE
FORTREATING/#$ANDTHREENONMANDATORY
TECHNIQUES
4HESPECIFICYOGICTECHNIQUE
FORTREATING/#$

REQUIRESBLOCKINGTHE
RIGHTNOSTRILATHUMBTIPORSECUREPLUGCAN
BEUSEDWITHSLOWDEEPINSPIRATIONTHROUGH
THELEFTNOSTRILBREATHRETENTIONANDSLOW
COMPLETEEXPIRATIONTHROUGHTHELEFTNOSTRIL
FOLLOWEDBYALONGBREATHHOLDINGOUTPERIOD
4HISPATTERNISCONTINUEDFORAMAXIMUMOF
MINUTES4HEPATIENTISINSTRUCTEDTOMAKE
EVERYEFFORTTOMAXIMIZETHEFOURPHASESOFTHE
BREATHCYCLEUNTILTHECOMPLETEBREATHCYCLE
EQUALSMINUTEWITHTHEFOURRESPECTIVE
PHASESEACHLASTINGSECONDSTHUSPERFECT
INGTHETECHNIQUE
4HISPURPORTEDLY/#$SPECIFICTECHNIQUEIS
ONEOFMANYMEDITATIONTECHNIQUESINTHE+9
SYSTEMTAUGHTBY9OGI"HAJANTHATARECLAIMED
TOBEUSEFULFORTREATINGSPECIFICPSYCHIATRIC
DISORDERS

3OMEOFTHEOTHERTECHNIQUESIN
THISPROTOCOLAREALSOCLAIMEDTOBEUSEFULFOR
TREATINGANXIETYDISORDERSASWELLASANGERAND
FEAR

4HEACTUALDATESOFDISCOVERYOFTHESE
TECHNIQUESAREUNKNOWN$33+LEARNED
THE/#$SPECIFIC+9TECHNIQUEINDUR
INGHISEARLYYEARSOFTRAININGWITHTHISYOGIC
SYSTEM(EFIRSTTESTEDITWITHTHEREMAINDEROF
THEPROTOCOLINANUNCONTROLLEDTRIAL

'ROUP WAS INSTRUCTED BY,%2A
LICENSEDTHERAPISTWITHYEARSOFPERSONAL
ANDCLINICALEXPERIENCEWITHTHEPOPULAR
2ELAXATION2ESPONSE22

AND-INDFULNESS
-EDITATION--TECHNIQUES
'ROUP
USEDEACHOFTHESETECHNIQUESFORMINUTES
"RIEFLYDESCRIBED22AND--ARERELATIVELY
PASSIVETECHNIQUES22REQUIRESACONSTANT
MENTALFOCUSANDREPETITIONOFASELFSELECTED
SPECIALWORDORPHRASE--REQUIRESTHE
CONSCIOUSOBSERVATIONOFTHOUGHTSWHILETHE
INDIVIDUALPASSIVELYOBSERVESTHEINSPIRATION
ANDEXPIRATIONOFTHEBREATHCYCLE
!SSESSMENTS
6ARIOUSPSYCHOLOGICALTESTSWEREADMINIS
TEREDASSELFRATINGMEASURES4HE9"/#3
MEASURESBOTHOBSESSIONSANDCOMPULSIONS
ANDALSOYIELDSACOMBINEDORTOTALSCORE4HE
9"/#3WHICHISUSUALLYADMINISTEREDIN
ASEMISTRUCTUREDINTERVIEWWASGIVENHERE
INAGROUPFORMATWITHEXPLANATIONAFTERTHE
9"/#3SYMPTOMSCHECKLIST)NARECENT
REVIEW OF STUDIES
EMPLOYMENT OF THE
9"/#3ASACOMPUTERADMINISTEREDCLINI
CALRATINGSCALEANDATALKINGCOMPUTERTELE
PHONEADMINISTEREDVERSIONWERECOMPARED
WITHTHESTANDARDCLINICIANADMINISTERED
VERSION2ESULTSSHOWEDNOSIGNIFICANTDIFFER
ENCEINTHEMODESOFADMINISTRATION
4HE3#,2INCLUDESASCALEFOROBSES
SIONSANDCOMPULSIONS/#ASWELLASTHE
'3)COMPOSITETHATREFLECTSNINESCALES
OBSESSIONSCOMPULSIONSANXIETYDEPRESSION
PARANOIDIDEATIONSOMATIZATIONINTERPER
SONALSENSITIVITYHOSTILITYPHOBICANXIETYAND
PSYCHOTICISM4HE0ROFILEOF-OOD3CALE
0/-3
MEASURESSIXVARIABLESTENSION
&EATURE!RTICLE/RIGINAL2ESEARCH
h4HE+9PROTOCOL
SHOWEDSIGNIFICANTLY
GREATERIMPROVEMENT
ONTHE9"/#3BOTH
3#,2SCALESAND
THE0/-3ANDGREATER
BUTNONSIGNIFICANT
IMPROVEMENTONTHE
033AND0),SCALESv
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

DEPRESSIONANXIETYVIGORFATIGUEANDCONFU
SIONTHATAREREPRESENTEDBYTHE4OTAL-OOD
$ISORDER4-$INDEX4HE0ERCEIVED3TRESS
3CALE033

MEASURESTHELEVELOFSTRESSTHAT
THEPATIENTPERCEIVES&INALLYTHE0URPOSEIN
,IFE0),

TESTMEASURESHOWMUCHPURPOSE
ANDMEANINGTHEPATIENTPERCEIVESINHISOR
HERLIFE"OTHTHE9"/#3AND3#,2/#
HAVEBEENSHOWNTOBEINTERNALLYCONSISTENT
ANDSENSITIVETOCHANGESWITHBEHAVIORAL
MEASURES

!LLTESTSWEREADMINISTEREDTOALLPATIENTS
ASONEGROUPATBASELINEPRIORTOTHEIRKNOW
INGTHEIRGROUPASSIGNMENTSWEEKSPRIOR
TOTHERAPY4HEFIRSTMONTHTESTSWEREALSO
ADMINISTEREDTOTHETWOGROUPSTOGETHER
&EATURE!RTICLE/RIGINAL2ESEARCH
&)'52%2%#25)4-%.42!.$/-):!4)/.!.$!,,/#!4)/./&0!4)%.43

ADULTSREPONDEDTOCALLFORPATIENTSANDSCREENED

ADOLESCENTSSCREENED

ADULTSFAILEDTOMEETINITIALCRITERIA

ADOLESCENTFAILEDTOMEETCRITERIA
!TMONTHS.ADULTS
ADULTSLOSTADOLESCENTLOST
!TMONTHS.ADULTS
ADULTSLOST
!TMONTHS.ADULTS
ADULTLOST
!TMONTHSFINALEND.ADULTS
ADULTSADOLESCENTADDAMONTHMERGING
!TMONTHMERGINGOFGROUPSTO+UNDALINIYOGA.
ADULTSFROM'ROUPADULTSFROM'ROUPNEW
ADULTSNEWADOLESCENTBOXTORIGHT
"EFOREMONTHTESTINGADULTSADOLESCENTLOST
2ELAXATION2ESPONSE-INDFULNESS-EDITATION
'ROUP.ADULTS
ADULTSCOMPLETEDTREATMENT.
ADULTSLOSTTOSTUDYBEFOREMONTHTESTING.
+UNDALINI9
OGA'ROUP.ADULTS
ADOLESCENT
ADULTSCOMPLETEDTREATMENT.
ADULTSLOSTTOSTUDYBEFOREMONTHTESTING.ADOLESCENTLOST
2ANDOMIZATIONOF!DULTS

ADULTSFULFILLEDINITIALCRITERIA

ADOLESCENTSFULFILLEDINITIALCRITERIAAGETOADMITLATERWHENAGEMEETINGMINIMUMAGETO
PARTICIPATEIFSTUDYHASOPENINGS

ADULTSALLOCATEDTOTREATMENTAFTERCOMPLETINGPRETREATMENTASSESSMENT

ADOLESCENTSALLOCATEDTOTEATMENTAFTERCOMPLETINGPRETREATMENTASSESSMENT

ADULTSFAILEDTOENTERATPRETREATMENTASSESSMENT

ADULTSACTUALLYPARTICIPATEDENTEREDRANDOMIZATIONTOTREATMENT

ADULTSFAILEDTOENTERTREATMENT

ADOLESCENTACTUALLYPARTICIPATEDENTEREDTREATMENT

ADOLESCENTFAILEDTOENTERTREATMENT
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

-ASKINGAND2ANDOMIZATION
/NTHESAMEEVENINGIMMEDIATELYAFTER
BASELINETESTINGPATIENTSWEREMATCHEDFOR
AGESEXANDMEDICATIONSTATUS!FTERFORMING
MATCHEDGROUPSGROUPTOTHERAPYPAIRINGS
WEREDETERMINEDBYACOINTOSS0ARTICIPANTS
HADNOKNOWLEDGEOFTHEMEDITATIONPROTOCOL
CONTENTSPRIORTOGROUPASSIGNMENTSOROFTHE
CONTENTOFTHEOTHERPROTOCOLAFTERRANDOM
IZATION$33+KNEWTHECONTENTSOFBOTH
PROTOCOLS,%2WASNOTINFORMEDABOUTTHE
PROTOCOLCONTENTFORGROUP
4REATMENT'ROUPS
4HEFLOWCHART&IGUREDESCRIBESTHE
RECRUITMENTRANDOMIZATIONANDALLOCATIONOF
PATIENTS4ABLEDESCRIBESDEMOGRAPHICSOF
THEPATIENTSINGROUPSANDINPHASETHE
FIRSTMONTHPERIODANDPHASEFOLLOWING
MERGEROFTHEGROUPSATMONTHS4WENTYONE
ADULTSWOMENSEVENMENANDONEADOLES
CENTGIRLPATIENTAGEDYEARSENROLLEDIN
PHASE)NPHASETWOADULTWOMENPATIENTS
ANDANDONEADOLESCENTBOYPATIENT
AGEDYEARSENTEREDTHEPROTOCOLALONGWITH
ONEWOMANPATIENTWHOHADDROPPEDOUT
AFTERWEEKSWITHGROUP
/FTHEPATIENTSHADRECEIVEDONEOR
MOREPRIORFORMSOFTHERAPYMEDICATION"4
ANDORPSYCHOTHERAPYFOR/#$ANDALLBUT
THREEBEGANEXPERIENCINGSYMPTOMSDURING
EARLYCHILDHOODORADOLESCENCE4HEPATIENT
POPULATIONHADACHARACTERISTICARRAYOF/#
SYMPTOMSANDSEVERITIESALLPRESENTED
WITHMULTIPLEOBSESSIONSANDCOMPULSIONS
3EE3HANNAHOFF+HALSA
FORACOMPLETE
DESCRIPTIONOFTHESE9"/#3OBSESSIONSAND
COMPULSIONS&OURPATIENTSAND
ALSOHADTRICHOTILLOMANIA
!TTHEBEGINNINGOFPHASEGROUPCON
SISTEDOFPARTICIPANTSINCLUDINGEIGHT
WOMENANDTHEADOLESCENTGIRL4ABLE
PATIENTSnAND3UBSEQUENTLYPRIOR
TOTHREEMONTHSONEPATIENTPATIENTAGED
&EATURE!RTICLE/RIGINAL2ESEARCH
4!",%0!4)%.4$%-/'2!0()#3
(ISTORYo
 !GEAT 2ELATIVES
0ATIENT !GE /NSET -ARITAL 0SYCHIATRIC 0HYSICAL 7ITH
.O 3EX 9EARS9EARS "4 -EDS 0SYCH%MPLOYED 3TATUS (ISTORY $ISEASE /#$
 &      M $EP "0 
 &      04 $ 
 &    34 3 "0
 -     &4 3
 &  #H   34 3 $EP!NR"UL
 &  S   M
 -     34 3 
 &      &4 M
 &     &4 M  "0
 -      3 30$EP!$$ #&3 
 &     04 $
 &     &4 M $EP "0 
 -     04 $ "$
 &  4EENS   M 3$
 -     &4 3
 -      &4 M 
 &    &4 M $EP
 -     &4 M $EP 
 &  #H   34 3 $EP 
 &  #H $
 &     3 !NR"UL
 &  #H   34 3 $EP
 &   04 M 
 &  #H   34 3 $EP!$($
 -     34 3 !$($$EP43
"4BEHAVIORAL THERAPY -EDSPREVIOUS TREATMENT WITH MEDICATION 0SYCHPREVIOUS PSYCHOTHERAPY &FEMALE -MALE CHCHILDHOOD ONSET &4FULL
TIME 04PARTTIME 34STUDENT MMARRIED $DIVORCED 3SINGLE $EPDEPRESSION !NRANOREXIA "ULBULIMIA 30SOCIAL PHOBIA !$$ATTENTION
DEFICIT DISORDER "$BIPOLAR DISORDER 3$SLEEP DISORDER !$($ATTENTION DEFICITHYPERACTIVITY DISORDER 434OURETTES SYNDROME "0BACK PAIN
#&3CHRONICFATIGUESYNDROME
4HEMEANAGEOFTHEPARTICIPANTSWASYEARS3$THEMEANAGEOF/#$ONSETWHENKNOWNWASYEARS3$
o
/VERALL OF PARTICIPANTSHAD PREVIOUSLY BEEN TREATEDWITH "4 HADRECEIVED MEDICATION AND HAD TRIED SOMEFORM OFINDIVIDUALLY BASED
PSYCHOTHERAPY )N ADDITION  WERE EITHER EMPLOYED OR STUDENTS  WERE MARRIED  WERE SINGLE AND  WERE CURRENTLY DIVORCED
&IFTYTWOPERCENTHADAHISTORYOFAPSYCHIATRICDISORDEROTHERTHAN/#$HADACURRENTPHYSICALDISORDERANDHADARELATIVEWITH/#$
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

YEARSWASELIMINATEDFROMTHESTUDYDUE
TOHERAPPARENTNEEDTOINCREASEHERDOSEOF
ABENZODIAZEPINE'ROUPPATIENTSn
INCLUDEDADULTSSIXWOMEN4HEMEAN
AGEWASYEARSSTANDARDDEVIATION
;3$=NRANGEnFORTHEGROUP
ADULTSANDYEARS3$N
RANGEnFORTHEGROUPADULTS%ACH
GROUPINITIALLYHADSIXADULTSTREATEDPHARMA
COLOGICALLYFOR/#$

3TATISTICAL!NALYSIS
7ECHOSETHE9"/#3ASTHEPRIMARYOUT
COMEMEASUREFORHYPOTHESISTESTINGATTHE
LEVELOFSIGNIFICANCETWOTAILED3TUDENTS
TTEST7EBASEDOURPOWERANALYSISFORGROUP
SIZESONOURPREVIOUSPILOTSTUDY

ANDFOUND
THATASAMPLESIZEOFEIGHTSUBJECTSWOULD
ALLOWUSTOTESTOURHYPOTHESISWITHα
ANDAPOWERORGREATER3TATISTICALANALY
SESWEREPERFORMEDUSINGTWOTAILED3TUDENTS
TTESTSWITH0#).&/TIMEORIENTED
DATAMANAGEMENTANALYSISSYSTEMSOFTWARE
2ETRIEVER$ATA3YSTEMS3EATTLE7ASHAND
"IOMEDICAL$ATA0ACKAGE3TATISTICAL3OFTWARE
5NIVERSITYOF#ALIFORNIA0RESS
2%35,43
0ARTICIPANT&LOW
4HESTUDYHADTWOPHASES0HASEWASA
MONTHRANDOMIZEDCONTROLLEDTRIALWITH
ONLYONEOFTHETWOTHERAPIESLEADINGTO
IMPROVEMENTS)N0HASETHEGROUPSWERE
MERGEDANDTHEMOREEFFICACIOUSPROTOCOL
FROMPHASEWASEMPLOYEDFORANADDITIONAL
MONTHS&IGUREDESCRIBESTHERECRUITMENT
RANDOMIZATIONANDALLOCATIONOFPATIENTS
!NALYSISOF0HASE)
4HESEPARATEGROUPBASELINEMEANS3$
ANDCONFIDENCEINTERVAL#)BASELINE
VALUESFORALLSCALESARELISTEDIN4ABLE
9"/#3SCORESSHOWEDTHATTHEGROUPSWERE
MATCHEDFORTHESEVERITYOF/#SYMPTOMS
$URINGTHEFIRSTMONTHPERIODEACHGROUP
HADTHREEADULTSWITHDRAWNOTINCLUDINGTHE
WOMANELIMINATEDFROMGROUPFORINCREASING
HERDOSEOFABENZODIAZEPINE4HREEPATIENTS
DROPPEDOUTOFGROUPAYEAROLDWOMAN
WITHA9"/#3SCOREOFAYEAROLD
WOMANWITHA9"/#3OFANDAYEAR
OLDMANWITHA9"/#3OF4HREEPATIENTS
ALSODROPPEDOUTOFGROUPAYEAROLD
WOMANWITHA9"/#3OFAYEAROLD
WOMANWITHA9"/#3OFANDAYEAR
OLDMANWITHA9"/#3OF4HEGROUP
ADOLESCENTYEAROLDGIRLWITHA9"/#3
OFALSOWITHDREW
$ROPOUTSCHOSENOTTORETAKETESTSLEAVING
EACHGROUPWITHSEVENADULTS4HERECALCULATED
MEANBASELINE9"/#3SCORESWEREFOR
THESEVENADULTSINGROUP3$#)
nANDFORTHESEVENADULTS
INGROUP3$#)n
4HETWONEWMEANSWERETESTEDFORSTATISTICAL
DIFFERENCESUSINGATWOTAILEDINDEPENDENT
GROUPS3TUDENTSTTESTTHEDIFFERENCESWERE
NOTSIGNIFICANTT0
'ROUPDIFFERENCESPREVSPOSTDIFFER
ENCESANDTHEGROUPINTERACTIONFORTHEFIRST
MONTHSOFTHERAPYWEREEVALUATEDUSINGTHE
9"/#34HEMONTHMEANTOTAL9"/#3
SCORESWEREFORGROUP3$.
#)nANDFORGROUP
3$.#)n5SING
&EATURE!RTICLE/RIGINAL2ESEARCH
4!",%!$5,4-/.4("!3%,).%-%!352%3
'ROUPN 'ROUPN
-EAN3$ #) -EAN3$ #)
9"/#3
4OTALSOBSESSIONSCOMPULSIONS  n  n
/BSESSIONS  n  n
#OMPULSIONS  n  n
3#,2
/#SCALE  n  n
'3)SCALE  n  n
0/-34-$SCORE  n  n
033  n  n
0),  n  n
9"/#39ALE"ROWN /BSESSIVE #OMPULSIVE 3CALE 3#,23YMPTOM #HECKLIST 2EVISED /#OBSESSIVE COMPULSIVE '3)GLOBAL SEVERITY INDEX
0/-30ROFILEOF-OODS3CALE-$4OTAL-OOD$ISORDERINDEX0330ERCEIVED3TRESS3CALE0),0URPOSEIN,IFETEST
-EAN VALUES STANDARD DEVIATIONS 3$SAND  CONFIDENCE INTERVALS #)S FOR THE 9"/#3 TOTALS;OBSESSIONSITEMS n=  ;COMPULSIONSITEMSn=
3#,2RAWSCORESFOR/#AND'3)SCALES0/-3TOTALMOODDISORDERRAWSCORES033AND0),FORTHEMONTHBASELINESFORGROUPSANDWITHTHE
ORIGINALADULTPATIENTSINEACHGROUPBEFOREOTHERSWITHDREW.INGROUPFORTHE9"/#3ONLYINCLUDESTHEADULTWOMANELIMINATEDDUETODRUG
COMPLICATIONSANDTHEADOLESCENTGIRL!LLTESTSWERETAKENPRIORTOTHEPATIENTSKNOWLEDGEOFGROUPASSIGNMENTS
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

ATWOWAYMIXEDMODELANALYSISOFVARIANCE
WEFOUNDTHATTHEINTERACTIONTERMREFLECTING
THEPOTENTIALDIFFERENTIALEFFECTSOFEACHTHER
APYWASSIGNIFICANT&;=0
INDICATINGTHATTHECHANGEINGROUPWAS
GREATERTHANTHATINGROUP4HEMEANGROUP
CHANGESIN9"/#3TOTALSFROMBASELINETO
MONTHSWEREFORGROUP3$
#)nANDFORGROUP
3$#)TO!TWO
TAILEDPAIRED3TUDENTSTTESTSHOWEDASIG
NIFICANTIMPROVEMENTOFT
0FORGROUPANDONLYAPOSITIVE
BUTNONSIGNIFICANTIMPROVEMENTOFFOR
GROUPT0
!NINTENTTOTREATANALYSISFORTHE9"/#3
USINGAPAIRED3TUDENTSTTESTTWOTAILEDWAS
PERFORMEDFORGROUP.ADULTSAND
ADOLESCENTANDGROUP.ADULTS4HE
MONTHBASELINESCORESFORTHOSELEAVINGTHE
STUDYWERECARRIEDFORWARDTOMONTHS4HE
GROUPMONTHMEANWAS3$
#)nANDTHEMONTH
MEANWAS3$#)n
4HEGROUPMONTHMEANWAS
3$#)nANDTHE
MONTHMEANWAS3$
#)n'ROUPSHOWEDASIGNIFI
CANT9"/#3IMPROVEMENTOFT
0ANDGROUPSHOWEDAPOSITIVEBUT
NONSIGNIFICANTTRENDTOWARDIMPROVEMENTOF
T0
4ABLESHOWSTHEMONTHANDMONTH
MEANSCORES3$AND#)SFORALLSCALES
ASWELLASTHERESULTSOFASTATISTICALhCOM
PLETERvANALYSISFORGROUPDIFFERENCESUSING
3TUDENTSINDEPENDENTGROUPSTTESTTWO
TAILED)TMUSTBENOTEDTHAT4ABLEDOESNOT
INCLUDETHERESULTSFORTHETHREEDROPOUTSFOR
EACHGROUPEXPLAININGTHEDIFFERENCESINN
VALUESCOMPAREDWITH4ABLE,OWERSCORES
ONALLSCALESEXCEPTTHE0),TESTREFLECTAN
IMPROVEDSTATE4HE+9PROTOCOLSHOWED
SIGNIFICANTLYGREATERIMPROVEMENTONTHE
9"/#3BOTH3#,2SCALESANDTHE
0/-3 AND GREATER BUT NONSIGNIFICANT
IMPROVEMENTONTHE033AND0),SCALES
!PAIRED3TUDENTSTTESTTWOTAILEDWAS
USEDTOCOMPAREWITHINGROUPDIFFERENCESAT
AND MONTHS FOR ALL SIX SCALES 4HE
9"/#33#,2/#AND'3)SCALES
0/-3033AND0),TESTALLSHOWEDSIGNIFI
CANCEFORTHEGROUPPROTOCOLN0
ANDRESPEC
TIVELY4HERESPECTIVEIMPROVEMENTSWERE

AND.OSCALEWASSIGNIFICANTFOR
GROUPNWITHRESPECTIVECHANGESOF
&EATURE!RTICLE/RIGINAL2ESEARCH
4!",%!$5,4-/.4(-%!."!3%,).%!.$-/.4(-%!352%3
)NDEPENDENT'ROUPS3TUDENTST4EST4WO4AILEDFOR#OMPARING%FFICACYOF'ROUPVS'ROUP
-ONTH3$#) -ONTH3$#) -EAN$IFFERENCE3$#) 06ALUE
9"/#34OTALS
'ROUPN n n n 
'ROUPN n n n
3#,2
/#SCALE
'ROUP n n n 
'ROUP n n n
'3)SCALE
'ROUP n n n 
'ROUP n n n
0/-3
'ROUP n n n 
'ROUP n n n
033
'ROUP n n n 
'ROUP n n n
0),
'ROUP n n n 
'ROUP n n n
9"/#39ALE"ROWN /BSESSIVE#OMPULSIVE 3CALE 3#,23YMPTOM #HECKLIST 2EVISED /#OBSESSIVECOMPULSIVE '3)GLOBAL SEVERITY INDEX
0/-30ROFILEOF-OODS3CALE0330ERCEIVED3TRESS3CALE0),0URPOSEIN,IFETEST
-EANVALUESSTANDARDDEVIATIONS3$SANDCONFIDENCEINTERVALS#)SFORGROUPSANDFOREACHTESTATTHEMONTHANDMONTHTESTPERIODS4HE
MONTHMEANSMINUSTHEMONTHMEANSAREEXPRESSEDASTHEDIFFERENCESCORESCHANGESCORESFOREACHGROUPANDSCALE4HEINDEPENDENTGROUPS3TUDENTS
TTESTTWOTAILEDWASUSEDTOCALCULATETHESIGNIFICANTDIFFERENCESFORIMPROVEMENTFOREACHGROUP4HE0VALUESAREPROVIDEDFORTHE9"/#33#,2/#
AND3#,2'3)0/-3033AND0),'ROUPIMPROVEMENTSWERESIGNIFICANTLYGREATERTHANGROUPFORTHE9"/#33#,2/#AND3#,2'3)AND
0/-3'ROUPIMPROVEDMORETHANGROUPONTHE033AND0),THEDIFFERENCESHOWEVERWERENOTSIGNIFICANT
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

AND
"ASEDONTHE9"/#3RESULTSTHE
GROUPSWEREMERGEDATTHEMONTHPERIOD
!NALYSISOF0HASE
!FTER MERGING THE STUDY POPULATION
INCLUDEDPATIENTSWHOCOMPLETEDMONTHS
OFTHEORIGINALADULTS/NEOFTHE
ADULTWOMENFROMGROUPWHOWITHDREWPRIOR
TOMONTHSPATIENTCHOSETOREENTER!LSO
THREENEWCANDIDATESWHOCOULDNOTPARTICI
PATEEARLIERDUETOTIMECONFLICTSENTEREDTHE
TRIALINPHASETWOWOMENPATIENTAGED
YEARSANDPATIENTAGEDYEARSAND
ONEADOLESCENTBOYWITH4OURETTESYNDROME
PATIENTAGEDYEARS0ATIENTSAND
WERETAKINGMEDICATIONFOR/#$%IGHTEEN
PATIENTSSTARTEDPHASEBUTTHREEPATIENTS
ANDWITHDREWAFTERSEVERALWEEKS
4HEMONTHMEANS3$AND#)SFROM
MONTHTOMONTHFORALLSUBJECTSCOMPLET
INGTESTSFORATLEASTTWOINTERVALSAREPRESENTED
IN4ABLE4HEMULTIPLERANGETESTRESULTSFOR
SIGNIFICANCELEVEL4UKEYTESTFORCOMPAR
INGTHEMEANSCORESATTHEVARIOUSINTERVALSARE
INTHELEGEND!NANALYSISOFVARIANCE!./6!
DEMONSTRATEDIMPROVEMENTSFORTHESEPATIENTS
ONTHE9"/#3&;=0
3#,2/#&;=0
3#,2'3)&;=0
0/-34-$SCALE&;=0
033&;=0AND 0),
&;=0)NADDITIONASUB
GROUPANALYSISOFTHESEVENPATIENTSINITIALLY
INGROUPSHOWEDAIMPROVEMENTINTHE
9"/#3FORTHEFIRSTMONTHSUSINGTHE+9
PROTOCOL4HISPARALLELEDTHEIMPROVE
MENTFORTHESEVENPATIENTSORIGINALLYINGROUP
DURINGTHEIRFIRSTMONTHS
7EALSOCALCULATEDTHESTATISTICSSEPA
RATELYFORTHOSESUBJECTSWHOWEREORIGI
NALLYINGROUPOVERTHEIRMONTHSOF+9
ANDTHOSEORIGINALLYINGROUPINCLUDING
PATIENTWHOENTEREDTHESTUDYATMONTH
FORTHEIR MONTHSOF+94HE ONE
WAYREPEATEDMEASURES!./6!FORTHE9
"/#33#,2/#SCALE3#,2'3)
SCALE0/-3033AND0),TESTSRESPEC
TIVELYFORGROUPMONTHSTOWERE
&0&
0 & 0 
&0&
0AND&04HE
RESPECTIVEGROUPVALUESFORMONTHSTO
IEMONTHSOF+9THERAPYWERE
&0&
0 & 0 
&0&
0AND&0
"OTH POPULATIONS SHOWEDSIGNIFICANT
IMPROVEMENTSWITHUSEOFTHE+9PROTOCOL
FORALLSCALESUSINGAN!./6!7HENTHE
MONTHBASELINE.MEANWASCOMPARED
WITHTHEMONTHMEAN.THEIMPROVE
MENTSATMONTHSWEREONTHE9
"/#3ONTHE3#,2/#SCALE
ONTHE3#,2'3)SCALE
ON0/-3ON033ANDONTHE
0),TEST&ORTHESEPATIENTSTHE9"/#3
TOTALSINCLUDEDTHREESCORESOFONESCOREOF
TWOSCORESOFONESCOREOFANDONESCORE
EACHOFAND
3IXOFTHEPATIENTSWHOENTEREDTHE
PROTOCOLWHILETAKINGMEDICATIONCOMPLETED
THESTUDY4HREEOFTHESESIXWEREFREEOF
MEDICATIONFORAMINIMUMOFMONTHSPRIOR
TOSTUDYEND4HEOTHERSWEREABLETOREDUCE
THEIRMEDICATIONDOSAGE
&EATURE!RTICLE/RIGINAL2ESEARCH
4!",%!,,039#(/,/')#!,3#!,%-/.4().4%26!,-%!.6!,5%3!.$#/.&)$%.#%).4%26!,3
MONTH3$#) MONTH3$#) MONTH3$#) MONTH3$#) MONTH3$#) MONTH3$#)
9"/#3TOTALS n n n n n n
3#,2
/#SCALE n n n n n n
'3)SCALE n n n n n n
0/-34-$ n n n n n TO
033 n n n n n n
0), n n n n n n
9"/#39ALE"ROWN /BSESSIVE #OMPULSIVE 3CALE 3#,23YMPTOM #HECKLIST 2EVISED /#OBSESSIVECOMPULSIVE '3)GLOBAL SEVERITY INDEX
0/-30ROFILEOF-OOD3TATES0330ERCEIVED3TRESS3CALE0),0URPOSEIN,IFESCALE
4HEMEANANDSTANDARDDEVIATION3$ANDCONFIDENCEINTERVALS#)SAREPROVIDEDFOREACHSCALEFORALLMONTHINTERVALMEASURES.
ANDFORTHEANDMONTHMEASURESRESPECTIVELY2EFLECTSPARTICIPANTSWHOREMAINEDINTHESTUDYFORATLEASTTWOMONTHTESTINTERVALS
4HE9"/#3MULTIPLERANGETESTRESULTSFORSIGNIFICANCELEVEL4UKEYTESTSHOWTHATMONTHMONTHMONTHMONTHMONTHMONTH
4HE 3#,2/# SCALE SHOWS THAT MONTH      MONTH MONTH   MONTH MONTHMONTH AND THE 3#,2'3) SCALE SHOWS
THATMONTHMONTH4HE0/-34-$SCORESSHOWTHATMONTHMONTHMONTHMONTHMONTHMONTH4HE033SHOWSTHAT
MONTHMONTHMONTHMONTHMONTHMONTH4HE0),SHOWSTHATMONTHMONTHMONTHMONTHMONTH
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

$)3#533)/.
4HEPRESENTINVESTIGATIONANDOURUNCON
TROLLEDSTUDY

YIELDEDSIMILARRESULTSDEM
ONSTRATINGREPRODUCIBILITYANDSUGGESTING
THATTHE+9PROTOCOLHASTHERAPEUTICVALUE
WITHOUTAPPARENTSIDEEFFECTS3INCETHE
GROUPUSING22AND--SHOWEDNOSIGNIFI
CANTIMPROVEMENTITCANBEASSUMEDTHAT
THEIMPROVEMENTSINTHE+9GROUPARENOT
THECONSEQUENCEOFAPLACEBOEFFECTOROF
ATTENTIONBUTRATHERATHERAPYSPECIFICFACTOR
7HILETHE+9PROTOCOLINCLUDEDATECHNIQUE
CLAIMEDBYYOGISTOBESPECIFICFOR/#$
THISPROTOCOLWASCOMPLEXTHEREFOREITIS
NOTCLEARWHICHCOMPONENTSLEDTOEFFICACY
3TUDIESEVALUATINGSUBJECTSONTHEBASISOF
ELECTROENCEPHALOGRAPHY

MAGNETOENCEPHA
LOGRAPHY-%'

COGNITIVEPERFORMANCE

ANDMOOD

ALLDEMONSTRATETHATLEFTNOSTRIL
BREATHINGTECHNIQUESSELECTIVELYSTIMULATE
THERIGHTHEMISPHEREOFTHEBRAIN4HERESULTS
OFOTHERREVIEWS

IDENTIFYRIGHTHEMISPHERIC
ABNORMALITIESWITH/#$

SUGGESTINGTHATTHE
EFFICACYOFTHISYOGICTECHNIQUEMAYBEDUETO
ARELATEDEFFECT/URPRELIMINARYUNPUBLISHED
-%'RESULTSONTHEEFFECTSOFTHEPURPORTEDLY
/#$SPECIFICLEFTNOSTRILBREATHINGTECHNIQUE
INATRAINEDNORMALSUBJECTSUGGESTTHATWHILE
STIMULATIONOFTHERIGHTHEMISPHEREISDIFFUSE
ANDDRAMATICASTRONGEFFECTONTHEFRONTAL
ANDPREFRONTALRIGHTHEMISPHEREMAYHELPTO
COMPENSATEFORTHE/#$RELATEDDEFECT
/URRESULTSAREENCOURAGINGWHENCOMPARED
WITHTHOSEFROMARECENTMULTICENTERDOUBLE
BLINDPLACEBOCONTROLLEDFLUVOXAMINESTUDY

THATSHOWEDA9"/#3IMPROVEMENTFOR
ACTIVETHERAPYNMEANCHANGEAND
AIMPROVEMENTFORPLACEBONMEAN
CHANGE/URMEAN9"/#3CHANGEOF
OVERMONTHSWITHOURCON
TROLGROUPMAYBEAPLACEBOEFFECT(OWEVER
THE+9PROTOCOLCHANGEATMONTHS
NMEANCHANGEANDMONTHS
NMEANCHANGEISALSOWELLBEYOND
THETOPLACEBOEFFECTOBSERVEDINA
DOUBLEBLINDPLACEBOCONTROLLEDSTUDYOF
CLOMIPRAMINE

)NADDITIONINACOMPARISON
OFRESULTSFROMFOURMULTICENTERPLACEBOCON
TROLLEDTRIALSOFCLOMIPRAMINEFLUOXETINE
FLUVOXAMINEANDSERTRALINE'RIESTETAL

FOUND
RESPECTIVE9"/#3IMPROVEMENTSOF
ANDFORTHEBESTDOSECOMPARISONS
!MONGTHEPUBLISHEDSTUDIESON"4-ARKS

CONCLUDEDTHATTHISINTERVENTIONCONSISTENTLY
ACHIEVESARATINGOFMUCHIMPROVEDIN
TOOFPATIENTSFOLLOWINGBRIEFTREATMENT
4HESEIMPROVEMENTSAREMAINTAINEDAFTER
TOYEARSOFFOLLOWUP3UMMARIZINGSTUD
IESOF"4CONDUCTEDMOSTLYONANINPATIENT
BASISAROUNDTHEWORLDOVERTHELASTDECADES
"AER

CONCLUDEDTHATAPPROXIMATELYOF
/#$PATIENTShGETCONTROLOFTHEIRSYMPTOMSv
ANDTHATAREABLETOCOMPLETE"4/FTHE
REMAININGMOSTSUCCUMBTOEXTREMEFEAR
)NADDITION#OTTRAUX

FOUNDTHATONEQUAR
TEROFPATIENTSEITHERREFUSETREATMENTORDROP
OUTEARLYIN"4THERAPY/FTHOSEREMAININGIN
THERAPYDONOTIMPROVEANDOFTHE
IMPROVEDPATIENTSREQUIREhBOOSTERTREATMENTv
FORSOMESUBSEQUENTLOSSOFGAINS
4HEMAJORITYOFTHEABOVE"4STUDIESHOW
EVERINCLUDEDPATIENTSWHOSEPRIMARY/#$RIT
UALSWERECLEANINGANDCHECKING
WHICHARETHEMOSTEASILYTREATEDFORMSOF/#$
USING"4

)NADDITIONTHEEARLIER"4STUDIESDID
NOTUSETHE9"/#3THECURRENTGOLDSTANDARD
FORMEASURING/#$SEVERITY&URTHERMORETHE
ACUTEEFFECTSOFEXPOSUREANDRESPONSEPREVEN
TIONOFTENLEADTOANIMMEDIATEANDINCREASED
LEVELOFFEARANDANXIETYAFFECTINGTHEPATIENTS
WILLINGNESSTOCOMPLYWITHTREATMENT
/URPATIENTSHADDIVERSEANDMULTIPLE
/#SYMPTOMS&ORTHEPATIENTSWHOCOM
PLETEDMONTHSOFTHERAPYTHEMEAN9
"/#3OBSESSIONSCOREDECREASEDFROM
3$#)nATBASELINE
TO3$#)nAT
MONTHSCOMPULSIONSCORESDECREASEDFROM
3$#)nTO
3$#)n!LLPATIENTS
WERETREATEDIDENTICALLYTHUSELIMINATINGTHE
NEEDFORANINDIVIDUALIZEDTREATMENTPLAN
'ROUPTHERAPYREDUCESTHEFINANCIALCOSTS
TOTHEPATIENTANDMINIMIZESTHERAPISTTIME
HOWEVERTHETIMECOURSEFORTREATMENTISLONG
ANDREQUIRESNEARWEEKLYATTENDANCEANDCON
SIDERABLEHOMEWORKCOMPARABLETO"4/UR
EXPERIENCESHOWSTHATAPPROXIMATELYYEARIS
REQUIREDTOACHIEVEMAXIMALOUTCOMES4HIS
RESEARCHISPRELIMINARYANDFURTHERINVESTIGA
TIONMUSTBECONDUCTEDWITHLARGERPOPULATIONS
TESTINGVARIOUSCOMBINATIONSOF+9TECHNIQUES
TOPERHAPSREFINETHEPROTOCOLANDATTEMPT
TREATMENTWITHYOUNGERPATIENTS
#.3
&EATURE!RTICLE/RIGINAL2ESEARCH
h4HEPRESENT
INVESTIGATIONAND
OURUNCONTROLLED
STUDYYIELDEDSIMILAR
RESULTSDEMONSTRATING
REPRODUCIBILITYAND
SUGGESTINGTHATTHE+9
PROTOCOLHASTHERAPEUTIC
VALUEWITHOUTAPPARENT
SIDEEFFECTSv
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

2%&%2%.#%3
 2APOPORT *, 4HE WAKING NIGHTMARE AN OVERVIEW OF
OBSESSIVE COMPULSIVE DISORDER * #LIN 0SYCHIATRY

 2ASMUSSEN 3! %ISEN *, %PIDEMIOLOGY OF OBSESSIVE
COMPULSIVEDISORDER*#LIN0SYCHIATRY
 *ENIKE -! 0SYCHOTHERAPY OF THE PATIENT WITH OBSESSIVE
COMPULSIVE PERSONALITY DISORDER )N *ENIKE -! "AER ,
-INICHIELLO7%EDS/BSESSIVE#OMPULSIVE$ISORDERS4HEORY
AND-ANAGEMENT3T,OUIS-O-OSBY9EAR"OOK
 'OODMAN7+-C$OUGLE#*0RICE,(0HARMACOTHERAPY
OF OBSESSIVE COMPULSIVE DISORDER * #LIN 0SYCHIATRY

 *ENIKE-!0HARMACOLOGICTREATMENTOFOBSESSIVECOMPUL
SIVEDISORDERS0SYCHIATR#LIN.ORTH!M
 'OODMAN 7+ 0RICE ,( 2ASMUSSEN 3! ET AL 4HE
9ALE"ROWN /BSESSIVE #OMPULSIVE 3CALE !RCH 'EN
0SYCHIATRY
 'OODMAN7+-C$OUGLE#*"ARR,#!RONSON3#0RICE
,("IOLOGICALAPPROACHESTOTREATMENTRESISTANTOBSESSIVE
COMPULSIVEDISORDER*#LIN0SYCHIATRY
 0ATO -4 :OHAR+ADOUCH 2 :OHAR * -URPHY $,
2ETURN OF SYMPTOMS AFTER DISCONTINUATION OF CLOMIP
RAMINEIN PATIENTSWITHOBSESSIVECOMPULSIVE DISORDER
!M*0SYCHIATRY
 ,EONARD (, ET AL ! DOUBLEBLIND SUBSTITUTION DURING
LONGTERMCLOMIPRAMINETREATMENTINCHILDRENANDADO
LESCENTS!RCH'EN0SYCHIATRY
&ONTAINE 2 #HOUINARD ' &LUOXETINE IN THE LONGTERM
TREATMENT OF OBSESSIVE COMPULSIVE DISORDER 0SYCHIATR
!NN
+OBAK +! 'RIEST *( *EFFERSON *7 +ATZELNICK $*
(ENK(*"EHAVIORALVERSUSPHARMACOLOGICALTREATMENTS
OF OBSESSIVE COMPULSIVE DISORDER A METAANALYSIS
0SYCHOPHARMACOLOGY
/3ULLIVAN ' .OSHIRVANI ( -ARKS ) -ONTEIRO 7
,ELLIOTT03IXYEARFOLLOWUPAFTEREXPOSUREANDCLOMIP
RAMINETHERAPYFOROBSESSIVECOMPULSIVEDISORDER*#LIN
0SYCHIATRY
-ARKS )- 2EVIEW OF BEHAVIORAL PSYCHOTHERAPY !M *
0SYCHIATRY
3HANNAHOFF+HALSA$3"ECKETT,2#LINICALCASEREPORT
EFFICACYOFYOGICTECHNIQUESINTHETREATMENTOFOBSESSIVE
COMPULSIVEDISORDER)NT*.EUROSCI
$EROGATIS ,2 3YMPTOM #HECKLIST2EVISED
-INNEAPOLIS-INN.ATIONAL#OMPUTER3YSTEMS
3HANNAHOFF+HALSA$39OGICMEDITATIONTECHNIQUESARE
EFFECTIVEINTHETREATMENTOFOBSESSIVECOMPULSIVEDISOR
DERS)N(OLLANDER%3TEIN$EDS/BSESSIVE#OMPULSIVE
$ISORDERS%TIOLOGY$IAGNOSISAND4REATMENT.EW9ORK
.9-ARCEL$EKKER
$IAGNOSTICAND 3TATISTICAL-ANUALOF -ENTAL $ISORDERS
RD ED REV 7ASHINGTON $# !MERICAN 0SYCHIATRIC
!SSOCIATION
3HANNAHOFF+HALSA $3 3TRESS TECHNOLOGY MEDICINE A
NEW PARADIGM FOR STRESS AND CONSIDERATIONS FOR SELF
REGULATION)N"ROWN-2+OOB'2IVIER#EDS3TRESS
.EUROBIOLOGY AND .EUROENDOCRINOLOGY .EW 9ORK .9
-ARCEL$EKKER
"ENSON ( 4HE 2ELAXATION 2ESPONSE .EW 9ORK .9
-ORROW
+ABAT:INN*!NOUTPATIENTPROGRAMINBEHAVIORALMED
ICINEFORCHRONICPAINPATIENTSBASEDONTHEPRACTICEOF
MINDFULNESS MEDITATION THEORETICAL CONSIDERATIONS AND
PRELIMINARYRESULTS'EN(OSP0SYCHIATRY
+ABAT:INN*&ULL#ATASTROPHE,IVING5SINGTHE7ISDOM
OF9OUR"ODYAND-INDTO&ACE3TRESS0AINAND)LLNESS
.EW9ORK.9$ELACORTE0RESS
+OBAK +! 'REIST *( *EFFERSON *7 +ATZELNICK $*
#OMPUTERADMINISTEREDCLINICALRATINGSCALESAREVIEW
0SYCHOPHARMACOLOGY
-C.AIR$- ,ORR- $ROPPLEMAN,&0ROFILE OF-OODS
3CALE 3AN $IEGO #ALIF %DUCATIONAL AND )NDUSTRIAL
4ESTING3ERVICE
#OHEN3+AMARCK4-ERMELSTEIN2!GLOBALMEASURE
OFPERCEIVEDSTRESS0ERCEIVED3TRESS3CALE4HE*OURNAL
OF(EALTHAND(UMAN"EHAVIOR
#RUMBAUGH *# -AHOLICK ,4 0URPOSE IN ,IFE 4EST
4EST  &ORM ! -URFREESBORO 4ENN 0SYCHOMETRIC
!FFILIATES
7OODY323TEKETEE'#HAMBLESS$,2ELIABILITYAND
VALIDITYOFTHE9ALE"ROWN/BSESSIVE#OMPULSIVE3CALE
"EHAV2ES4HER
7OODY323TEKETEE'#HAMBLESS$,4HEUSEFULNESSOF
THEOBSESSIVECOMPULSIVESCALEOFTHE3YMPTOM#HECKLIST
2EVISED"EHAV2ES4HER
7ERNTZ $! "ICKFORD 2' 3HANNAHOFF+HALSA $3
3ELECTIVE HEMISPHERIC STIMULATION BY UNILATERAL FORCED
NOSTRILBREATHING(UMAN.EUROBIOLOGY
3HANNAHOFF+HALSA$3"OYLE-2"UEBEL-4HEEFFECTS
OFUNILATERALFORCEDNOSTRILBREATHINGONCOGNITION)NT*
.EUROSCI
*ELLA3!3HANNAHOFF+HALSA$3 4HE EFFECTSOF UNILAT
ERAL FORCED NOSTRILBREATHINGON COGNITIVE PERFORMANCE
)NT*.EUROSCI
3CHIFF""2UMP3!!SYMMETRICALHEMISPHERICACTIVA
TIONANDEMOTIONTHEEFFECTSOFUNILATERALFORCEDNOSTRIL
BREATHING"RAINAND#OGNITION
"REITER (# 2AUCH 3, +WONG ++ ET AL &UNCTIONAL
MAGNETIC RESONANCE IMAGING OF SYMPTOM PROVOCATION
INOBSESSIVECOMPULSIVEDISORDER!RCH'EN 0SYCHIATRY

'OODMAN 7+ +OZAK -* ,IEBOWITZ - 7HITE +,
4REATMENTOFOBSESSIVECOMPULSIVEDISORDERWITHFLUVOX
AMINE A MULTICENTER DOUBLEBLIND PLACEBOCONTROLLED
TRIAL)NT#LIN0SYCHOPHARMACOL
'RIEST *( *EFFERSON *7 2OSENFELD 2 'UTZMANN ,$
-ARCH *3 "ARKLAGE .% #LOMIPRAMINE AND OBSESSIVE
COMPULSIVE DISORDER A PLACEBOCONTROLLED DOUBLEBLIND
STUDYOFPATIENTS*#LIN0SYCHIATRY
'RIEST *( *EFFERSON *7 +OBAK +! +ATZELNICK $*
3ERLIN 2# %FFICACY AND TOLERABILITY OF SEROTONIN TRANS
PORT INHIBITORS IN OBSESSIVECOMPULSIVE DISORDER !RCH
'EN0SYCHIATRY
-ARKS )- 2EVIEW OF BEHAVIORAL PSYCHOTHERAPY !M *
0SYCHIATRY
"AER,'ETTING#ONTROL/VERCOMING9OUR/BSESSIONSAND
#OMPULSIONS"OSTON-ASS,ITTLE"ROWN#O
#OTTRAUX*"EHAVIORALPSYCHOTHERAPYFOROBSESSIVECOM
PULSIVE DISORDER )NTERNATIONAL 2EVIEW OF 0SYCHIATRY

"AER,-INICHIELLO7%"EHAVIORTHERAPYFOROBSESSIVE
COMPULSIVEDISORDER)N*ENIKE-!"AER,-INICHIELLO
7% EDS /BSESSIVE#OMPULSIVE $ISORDERS 4HEORY AND
-ANAGEMENT3T,OUIS-O-OSBY9EAR"OOK
&EATURE!RTICLE/RIGINAL2ESEARCH
hFURTHERINVESTIGATION
MUSTBECONDUCTED
WITHLARGERPOPULATIONS
TESTINGVARIOUSCOMBIN
ATIONSOF+9TECHNIQUES
TOPERHAPSREFINETHE
PROTOCOLANDATTEMPT
TREATMENTWITH
YOUNGERPATIENTSv
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
... An intervention consisting of a series of eight primary Kundalini yoga postural and breath exercises, as well as an OCDB exercise characterized by a specific left-nostril breathing meditation (Shannahoff- Khalsa, 2003;Shannahoff-Khalsa et al., 1999, 2019. TCTSY A protocol that integrates Hatha yoga with principles of trauma and attachment theory, and adopts numerous trauma-informed modifications, such as emphasizing a safe environment, empowering participants to make informed choices about their yoga postures, and refraining from the use of physical hands-on adjustments (Price et al., 2017). ...
... In an effort to investigate the efficacy of a Kundalini yoga protocol specifically adapted for the treatment of OCD (KY-OCD), D. S. Shannahoff- Khalsa et al. (1999) and D. S. Shannahoff- Khalsa (2003) conducted two 12-month long trials in the United States. One trial was an open, uncontrolled pilot study and the second was a randomized, comparisoncontrolled matched-groups trial. ...
... By 7 months after the start of the KY-OCD intervention, three of the participants were able to completely stop taking their medication and the remaining two had reduced their medication dose by 25%-50%. After the complete 12-month KY-OCD intervention, four of the five subjects were able to discontinue their medication with lasting improvements, and all participants reported significant improvement in perceived stress, anxiety, global symptom severity, and OCD symptomatology, with continuous improvement over the course of the study (D. S. Shannahoff- Khalsa et al., 1999). ...
Article
Full-text available
Yoga has shown promise as a widely practiced, readily accessible, low-stigma, and cost-effective means of managing stress and anxiety. However, mental health professionals and individuals who struggle with diagnosed anxiety disorders would benefit from evidence-based guidance about the effectiveness of yoga to manage these issues. This review of the empirical research literature examined the clinical utility of yoga as a treatment for anxiety-spectrum disorders, focusing on quantitative, comparison-controlled studies of yoga interventions. Studies eligible for inclusion either utilized yoga as the primary treatment intervention or as an adjunct to conventional treatment approaches, such as psychotherapy or pharmacotherapy. As a whole, the current research evidence supports the conclusion that yoga interventions are likely to be effective as both a complementary and stand-alone treatment for patients with anxiety-spectrum disorders. However, to further substantiate the use of yoga as an alternative to conventional, evidence-based therapies, additional research is needed to determine the relative efficacy of these treatment modalities.
... Kundalini yoga, in particular, has been shown to provide both immediate and long-term treatment from OCD symptoms (Shannahoff- Khalsa, 2003). Clinical investigations using Kundalini yoga meditation techniques show benefit in treating OCD, suggesting a viable alternative to established therapy procedures (Shannahoff- Khalsa et al., 1999). ...
Article
Full-text available
This comprehensive review explores the therapeutic potential of yoga in addressing obsessive compulsive disorder (OCD) and depression, prevalent psychiatric conditions with significant treatment challenges. Highlighting the global impact and limitations of conventional therapies for OCD, the paper introduces Complementary and Alternative Medicine (CAM), specifically yoga, as a promising solution. Examining various yoga forms, such as Kundalini yoga and Rajyoga meditation, the review cites clinical trials supporting yoga's positive impact on OCD symptoms. Additionally, it explores the efficacy of different yoga forms, including Sudarshankriya, in alleviating depressive symptoms. Emphasizing yoga's stress-reducing properties in anxiety disorders, the paper concludes by highlighting yoga's holistic and individualized nature, offering promising alternatives to traditional treatments for OCD and depression in mental health care.
... Yoga is effective in the prevention and management of stress and stress-related disorders (Davendra, 2014). Yoga has been shown to be effective in relieving symptoms of mental illness, including depression (Shapiro et al., 2007;Krishnamurthy and Telles, 2007;Woolery, Myers, Sternlieb, Zeltzer, 2004), anxiety (Smith et al., 2007), obsessive-compulsive disorder (Shannahoff-Khalsa et al., 1999) and ...
Article
Full-text available
The aim of this study is to investigate the effects of yoga exercises on body composition, flexibility, and quality of life in sedentary women. In line with this aim, the one-group pretest-posttest research design was used in the study. A total of 33 sedentary women who are between the ages of 20-47, live in Gaziantep, and started doing sports as of the beginning of pandemic restrictions voluntarily participated in our study. SF-36 Quality of Life questionnaire and body measurements were used as data collection tools. A program of yoga exercises was applied to participants three times a week for 10 weeks. At the end of the study, a statistical difference in favor of the posttest was determined between the mean values of the pretest and posttest in the quality of life questionnaire (p
Article
Full-text available
The evidence reported in review articles, this study highlights the most recent research on the impact of yoga therapies on many aspects of mental and physical health. Collectively, these reviews point to a variety of circumstances in which yoga might be advantageous, although further research is necessary. However, certain meta-analyses show the benefits of yoga therapies, and a number of relatively high-quality randomized clinical trials (RCTs) show the advantages of yoga for pain-related impairment and mental health. Students frequently experience concentration and stress issues, which are indicators of academic challenges as well as other behavioral and emotional issues. Mind-body interventions such as yoga and meditation improve attention and reduce stress. In this study, we examined the impact of Hatha yoga on attention and stress. One important metric for assessing stress is cortisol.
Article
Full-text available
We study how obsessive-compulsive disorder (OCD) affects the complexity and time-reversal symmetry-breaking (irreversibility) of the brain resting-state activity as measured by magnetoencephalography (MEG). Comparing MEG recordings from OCD patients and age/sex matched control subjects, we find that irreversibility is more concentrated at faster time scales and more uniformly distributed across different channels of the same hemisphere in OCD patients than in control subjects. Furthermore, the interhemispheric asymmetry between homologous areas of OCD patients and controls is also markedly different. Some of these differences were reduced by 1-year of Kundalini Yoga meditation treatment. Taken together, these results suggest that OCD alters the dynamic attractor of the brain's resting state and hint at a possible novel neurophysiological characterization of this psychiatric disorder and how this therapy can possibly modulate brain function.
Article
Full-text available
We study how obsessive-compulsive disorder (OCD) affects the complexity and time-reversal symmetry-breaking (irreversibility) of the brain resting-state activity as measured by magnetoencephalography (MEG). Comparing MEG recordings from OCD patients and age/sex matched control subjects, we find that irreversibility is more concentrated at faster time scales and more uniformly distributed across different channels of the same hemisphere in OCD patients than in control subjects. Furthermore, the interhemispheric asymmetry between homologous areas of OCD patients and controls is also markedly different. Some of these differences were reduced by 1-year of Kundalini Yoga meditation treatment. Taken together, these results suggest that OCD alters the dynamic attractor of the brain's resting state and hint at a possible novel neurophysiological characterization of this psychiatric disorder and how this therapy can possibly modulate brain function.
Article
Yoga has been put to test in clinical medicine to build evidence. There has been a steep rise in yoga research through 2010, threefold in the next decade. Despite challenges, clinicians have explored yoga intervention in several disorders. The available data have been examined using meta-analysis when there are more studies. Psychiatric disorders treated with yoga have attracted more research. Some examples include depression, schizophrenia, anxiety, obsessive-compulsive disorder (OCD), somatoform pain, addiction, mild cognitive impairment, and elderly and childhood disorders. Current manuscript focuses on highlighting the major steps towards generating evidence that have led to integration of yoga into psychiatry practice. It also discusses various challenges and the way forward.
Chapter
Exercise is well known to be beneficial to physical health; however, increasing research indicates that physical exercise is also beneficial to brain health and may alleviate symptoms of mental disorders. This book, written by international experts, describes and explores the theory and practice of exercise intervention for different mental disorders across the life span. Drawing on evidence from basic neuroscience research, and enriched with findings from the latest clinical trials, the work provides clear descriptions of current practice and highlights ways to translate this knowledge into pragmatic advice for use in daily practice. The chapters cover a broad range of conditions including neurodevelopmental disorders, depression, anxiety, psychosis and late life neurocognitive disorders. This book is for mental health clinicians including psychiatrists, psychologists, social workers, nurses, as well as internists, paediatricians and geriatricians seeking a comprehensive and individualized approach to treatment.
Chapter
Exercise is well known to be beneficial to physical health; however, increasing research indicates that physical exercise is also beneficial to brain health and may alleviate symptoms of mental disorders. This book, written by international experts, describes and explores the theory and practice of exercise intervention for different mental disorders across the life span. Drawing on evidence from basic neuroscience research, and enriched with findings from the latest clinical trials, the work provides clear descriptions of current practice and highlights ways to translate this knowledge into pragmatic advice for use in daily practice. The chapters cover a broad range of conditions including neurodevelopmental disorders, depression, anxiety, psychosis and late life neurocognitive disorders. This book is for mental health clinicians including psychiatrists, psychologists, social workers, nurses, as well as internists, paediatricians and geriatricians seeking a comprehensive and individualized approach to treatment.
Article
Full-text available
The aim of this study was to investigate the clinical efficacy of yogic techniques in the treatment of eight adults with obsessive-compulsive disorder (OCD). A specific yogic breathing pattern has been prescribed for the treatment of OCD, as well as others for treating generalized anxiety. A one year course of therapy was followed. Subjects improved on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) comparing baseline with three, six, nine, & 12 month results (one-way ANOVA for repeated measures, F(4, 12) = 3.343, p
Article
Full-text available
While clinician-administered symptom rating scales are the most commonly used outcome measures in pharmaceutical research, error variance due to poor inter-rater reliability increases the risk of type II errors in multi-center clinical trials. Such error variance could obscure true differences between active drug and placebo, or between two comparator compounds. Computer-administered versions of symptom rating scales originally designed to be administered by trained clinicians offer a solution to this problem. This paper reviews the empirical data on the reliability, validity and equivalence of computer-administered rating scales. Computer-administered versions of clinician-administered scales are now available for the assessment of depression, anxiety, obsessive-compulsive disorder, and social phobia. Validation studies support the reliability, validity and equivalence of these scales. Patient reaction has been positive, with patients generally more honest with and often preferring the computer for assessing sensitive areas such as suicide, alcohol or drug abuse, sexual behavior, or HIV related symptoms. Applications using Interactive Voice Response (IVR) technology facilitate longitudinal monitoring of patients without requiring office visits to collect data, increase the accessibility of information to the clinician, and the quality of patient care through more informed decision making. When used in accordance with established ethical guidelines, computers offer a reliable, inexpensive, accessible, and time-efficient means of assessing psychiatric symptoms.
Article
Full-text available
While clinician-administered symptom rating scales are the most commonly used outcome measures in pharmaceutical research, error variance due to poor inter-rater reliability increases the risk of type II errors in multi-center clinical trials. Such error variance could obscure true differences between active drug and placebo, or between two comparator compounds. Computer-administered versions of symptom rating scales originally designed to be administered by trained clinicians offer a solution to this problem. This paper reviews the empirical data on the reliability, validity and equivalence of computer-administered rating scales. Computer-administered versions of clinician-administered scales are now available for the assessment of depression, anxiety, obsessive-compulsive disorder, and social phobia. Validation studies support the reliability, validity and equivalence of these scales. Patient reaction has been positive, with patients generally more honest with and often preferring the computer for assessing sensitive areas such as suicide, alcohol or drug abuse, sexual behavior, or HIV related symptoms. Applications using Interactive Voice Response (IVR) technology facilitate longitudinal monitoring of patients without requiring office visits to collect data, increase the accessibility of information to the clinician, and the quality of patient care through more informed decision making. When used in accordance with established ethical guidelines, computers offer a reliable, inexpensive, accessible, and time-efficient means of assessing psychiatric symptoms.
Chapter
OCD has been viewed traditionally as resistant to conventional therapies. Fortunately, in recent years there have been advances in both the pharmacotherapy and behavioral therapy of OCD. For example, more than 50% of patients treated with potent serotonin reuptake inhibitors (SRIs) such as clomipramine (CMI) or fluvoxamine (FVX) are judged by blind raters as “much” or “very much” improved. The magnitude of improvement in these “responders” represents about a 40% decrease in obsessive-compulsive symptom severity, as reflected on the Yale-Brown Obsessive Compulsive Scale. On the other hand, OCD patients treated with norepinephrine reuptake inhibitors (e.g. desipramine) generally show no change. This contrasts sharply with the results of controlled trials in depression, in which drugs with very different profiles of monoamine reuptake inhibition are roughly equivalent in antidepressant efficacy. Studies of the efficacy and tolerability of SRIs in OCD will be reviewed with the goal of providing practical guidelines to the use of these medications in OCD. The use of “antidepressants” in the treatment of depression vs the treatment of OCD will be compared. Until large-scale studies have been conducted in which the anti-OC efficacy of the different potent SRIs can be compared directly, the initial choice of a medication treatment for an individual OCD patient may be based mostly on its sideeffects profile and availability. The implications of these treatment response data for the pathophysiology of OCD will also be discussed briefly.
Article
Background: Questions have been raised regarding the relative efficacy and tolerability of the different serotonin transport inhibitors in the treatment of obsessive-compulsive disorder. We compared the results from four large multicenter placebo-controlled trials of the serotonin transport inhibitors clomipramine hydrochloride (N=520), fluoxetine hydrochloride (N=355), fluvoxamine maleate (N=320), and sertraline hydrochloride (N=325) for the treatment of obsessive-compulsive disorder. Methods: Effect size was calculated by subtracting the end-point drug treatment mean change from the endpoint placebo mean change and dividing by the endpoint pooled change standard deviation. A test for overall differences between effect sizes was conducted, followed by all possible pairwise comparisons. The Yale-Brown Obsessive Compulsive Scale was the primary outcome measure for all four studies. Results: All four agents were significantly more effective than placebo, with clomipramine significantly more effective than the other three treatments, which did not differ in effect size. A significantly greater percentage of patients treated with clomipramine were rated much or very much improved than were patients treated with fluoxetine, fluvoxamine, or sertraline. Conclusion: While the results of this meta-analysis support the superiority of clomipramine, head-to-head, double-blind comparisons of these compounds would be the best test of comparative efficacy and tolerability.
Article
Background: The new technique of functional magnetic resonance imaging was used to investigate the mediating neuroanatomy of obsessive-compulsive disorder symptoms.Methods: Ten patients with obsessive-compulsive disorder and 5 normal subjects were studied via functional magnetic resonance imaging during control and provoked conditions. Data analysis entailed parametric and nonparametric statistical mapping.Results: Statistical maps (nonparametric; P<10-3) showed activation for 70% or more of patients with obsessive-compulsive disorder in medial orbitofrontal, lateral frontal, anterior temporal, anterior cingulate, and insular cortex, as well as caudate, lenticulate, and amygdala. No normal subjects exhibited activation in any brain region.Conclusions: Results of functional magnetic resonance imaging were consistent with past studies of obsessive-compulsive disorder that used other functional neuroimaging modalities. However, paralimbic and limbic activations were more prominent in the present study.
Article
• Twenty-six chilndren and adolescents with severe primary obsessive-compulsive disorder receiving long-term clomipramine hydrochloride maintenance treatment (mean±SD, 17.1±8.3 months; range, 4 to 32 months) entered an 8-month double-blind desipramine hydrochloride substitution study to assess the necessity of continued drug treatment. All patients received clomipramine for the first 3 months, then half continued with clomipramine therapy (nonsubstituted group) and half had desipramine blindly substituted for the next 2 months; all subjects again received clomipramine for the last 3 study months. Eight (89%) of nine of the substituted and only two (18%) of 11 of the nonsubstituted group subjects relapsed during the 2-month comparison period. Long-term clomipramine treatment seems necessary for this population of children and adolescents with obsessive-compulsive disorder. However, even patients receiving maintenance clomipramine treatment throughout the entire study had continued obsessivecompulsive symptoms, which varied in severity over time.
Article
• The Yale-Brown Obsessive Compulsive Scale was designed to remedy the problems of existing rating scales by providing a specific measure of the severity of symptoms of obsessivecompulsive disorder that is not influenced by the type of obsessions or compulsions present. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms) (total range, 0 to 40), with separate subtotals for severity of obsessions and compulsions. In a study involving four raters and 40 patients with obsessive-compulsive disorder at various stages of treatment, interrater reliability for the total Yale-Brown Scale score and each of the 10 individual items was excellent, with a high degree of internal consistency among all item scores demonstrated with Cronbach's α coefficient. Based on pretreatment assessment of 42 patients with obsessive-compulsive disorder, each item was frequently endorsed and measured across a range of severity. These findings suggest that the Yale-Brown Scale is a reliable instrument for measuring the severity of illness in patients with obsessive-compulsive disorder with a range of severity and types of obsessive-compulsive symptoms.
Article
26 female and 24 male (aged 21–49 yrs) treatment resistant, obsessive-compulsive disorder outpatients were administered fluoxetine (FLU [20–200 mg]), a serotonin reuptake blocker, for 12–20 mo. Results suggest a persistent antiobsessive effect of FLU. The relapse rate observed after discontinuation of FLU was lower than that found for clomipramine discontinuation (M. Pato et al, 1988). The only clinically significant side effect of FLU treatment was tremor in 8 Ss, which interfered with their daily functioning. Findings suggest a linear dose–response relationship for FLU's antiobsessive-compulsive effect. (PsycINFO Database Record (c) 2012 APA, all rights reserved)